129 related articles for article (PubMed ID: 17096299)
1. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
2. Macrocyclic inhibitors of hsp90.
Johnson VA; Singh EK; Nazarova LA; Alexander LD; McAlpine SR
Curr Top Med Chem; 2010; 10(14):1380-402. PubMed ID: 20536417
[TBL] [Abstract][Full Text] [Related]
3. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers.
Jhaveri K; Taldone T; Modi S; Chiosis G
Biochim Biophys Acta; 2012 Mar; 1823(3):742-55. PubMed ID: 22062686
[TBL] [Abstract][Full Text] [Related]
4. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors.
Garg G; Forsberg LK; Zhao H; Blagg BSJ
Chemistry; 2017 Nov; 23(65):16574-16585. PubMed ID: 28940589
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of resorcinyl-imidazole Hsp90 inhibitor design.
Gedgaudas M; Kaziukonytė P; Kairys V; Mickevičiūtė A; Zubrienė A; Brukštus A; Matulis D; Kazlauskas E
Eur J Med Chem; 2024 Jul; 273():116505. PubMed ID: 38788300
[TBL] [Abstract][Full Text] [Related]
6. Plant-Based HSP90 Inhibitors in Breast Cancer Models: A Systematic Review.
Zarguan I; Ghoul S; Belayachi L; Benjouad A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791506
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein 90 inhibitors in the treatment of cancer: current status and future directions.
Jhaveri K; Ochiana SO; Dunphy MP; Gerecitano JF; Corben AD; Peter RI; Janjigian YY; Gomes-DaGama EM; Koren J; Modi S; Chiosis G
Expert Opin Investig Drugs; 2014 May; 23(5):611-28. PubMed ID: 24669860
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of di-sansalvamide A derivatives: synthesis, structure-activity relationship, and mechanism of action.
Alexander LD; Sellers RP; Davis MR; Ardi VC; Johnson VA; Vasko RC; McAlpine SR
J Med Chem; 2009 Dec; 52(24):7927-30. PubMed ID: 20014866
[TBL] [Abstract][Full Text] [Related]
9. Recent developments of HSP90 inhibitors: an updated patent review (2020-present).
Liu J; Shu H; Xia Q; You Q; Wang L
Expert Opin Ther Pat; 2024; 34(1-2):1-15. PubMed ID: 38441084
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting the molecular evolution of cancer through HSP90.
Martins AS; Davies FE; Workman P
Oncotarget; 2012 Oct; 3(10):1054-6. PubMed ID: 23175477
[No Abstract] [Full Text] [Related]
11. Recent Developments and Future Perspectives of Purine Derivatives as a Promising Scaffold in Drug Discovery.
Rana N; Grover P; Singh H
Curr Top Med Chem; 2024; 24(6):541-579. PubMed ID: 38288806
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of 4-(2-hydroxypropyl)piperazin-1-yl) derivatives as Hsp90 inhibitors.
Cherfaoui B; Guo TK; Sun HP; Cheng WL; Liu F; Jiang F; Xu XL; You QD
Bioorg Med Chem; 2016 Jun; 24(11):2423-2432. PubMed ID: 27134115
[TBL] [Abstract][Full Text] [Related]
13. Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC; Lopes EC; Yang SN; Hatzi K; Bunting KL; Tsikitas LA; Mallik A; Robles AI; Walling J; Varticovski L; Shaknovich R; Bhalla KN; Chiosis G; Melnick A
Nat Med; 2024 May; 30(5):1503. PubMed ID: 38570701
[No Abstract] [Full Text] [Related]
14. Purine-scaffold Hsp90 inhibitors.
Taldone T; Chiosis G
Curr Top Med Chem; 2009; 9(15):1436-46. PubMed ID: 19860732
[TBL] [Abstract][Full Text] [Related]
15. Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches.
Sumi MP; Ghosh A
Cells; 2022 Mar; 11(6):. PubMed ID: 35326427
[TBL] [Abstract][Full Text] [Related]
16. New Perspectives of Gene Therapy on Polyglutamine Spinocerebellar Ataxias: From Molecular Targets to Novel Nanovectors.
Borbolla-Jiménez FV; Del Prado-Audelo ML; Cisneros B; Caballero-Florán IH; Leyva-Gómez G; Magaña JJ
Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371710
[TBL] [Abstract][Full Text] [Related]
17. Chaperone-Based Therapies for Disease Modification in Parkinson's Disease.
Friesen EL; De Snoo ML; Rajendran L; Kalia LV; Kalia SK
Parkinsons Dis; 2017; 2017():5015307. PubMed ID: 28913005
[TBL] [Abstract][Full Text] [Related]
18. Regulation and function of the human HSP90AA1 gene.
Zuehlke AD; Beebe K; Neckers L; Prince T
Gene; 2015 Oct; 570(1):8-16. PubMed ID: 26071189
[TBL] [Abstract][Full Text] [Related]
19. White matter loss in a mouse model of periventricular leukomalacia is rescued by trophic factors.
Espinosa-Jeffrey A; Barajas SA; Arrazola AR; Taniguchi A; Zhao PM; Bokhoor P; Holley SM; Dejarme DP; Chu B; Cepeda C; Levine MS; Gressens P; Feria-Velasco A; de Vellis J
Brain Sci; 2013 Nov; 3(4):1461-82. PubMed ID: 24961618
[TBL] [Abstract][Full Text] [Related]
20. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not α-synuclein-induced neuronal cell loss.
McFarland NR; Dimant H; Kibuuka L; Ebrahimi-Fakhari D; Desjardins CA; Danzer KM; Danzer M; Fan Z; Schwarzschild MA; Hirst W; McLean PJ
PLoS One; 2014; 9(1):e86048. PubMed ID: 24465863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
